HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Neuroproteome changes after ischemia/reperfusion injury and tissue plasminogen activator administration in rats: a quantitative iTRAQ proteomics study.

Abstract
The thrombolytic, recombinant tissue plasminogen activator (rt-PA) is the only approved therapy for acute ischemic stroke (AIS). When administered after AIS, rt-PA has many adverse pleiotropic actions, which are currently poorly understood. The identification of proteins showing differential expression after rt-PA administration may provide insight into these pleiotropic actions. In this study we used a 2D-LC MS/MS iTRAQ proteomic analysis, western blotting, and pathway analysis to analyze changes in protein expression 24-hours after rt-PA administration in the cortical brain tissue of 36 rats that underwent a sham or transient middle cerebral artery occlusion surgery. After rt-PA administration we reported alterations in the expressions of 18 proteins, many of which were involved in excitatory neurotransmitter function or cytoskeletal structure. The expression changes of GAD2 and EAAT1 were validated with western blot. The interactions between the identified proteins were analyzed with the IPA pathway analysis tool and three proteins: DPYSL2, RTN4, and the NF-kB complex, were found to have characteristics of being key proteins in the network. The differential protein expressions we observed may reflect pleiotropic actions of rt-PA after experimental stroke, and shine light on the mechanisms of rt-PA's adverse effects. This may have important implications in clinical settings where thrombolytic therapy is used to treat AIS.
AuthorsZamir Merali, Meah MingYang Gao, Tim Bowes, Jian Chen, Kenneth Evans, Andrea Kassner
JournalPloS one (PLoS One) Vol. 9 Issue 5 Pg. e98706 ( 2014) ISSN: 1932-6203 [Electronic] United States
PMID24879061 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Excitatory Amino Acid Transporter 1
  • Intercellular Signaling Peptides and Proteins
  • Myelin Proteins
  • NF-kappa B
  • Nerve Tissue Proteins
  • Neurotransmitter Agents
  • Nogo Proteins
  • Proteome
  • Recombinant Proteins
  • Rtn4 protein, rat
  • Slc1a3 protein, rat
  • collapsin response mediator protein-2
  • Tissue Plasminogen Activator
  • Glutamate Decarboxylase
  • glutamate decarboxylase 2
Topics
  • Animals
  • Brain (metabolism)
  • Brain Ischemia (genetics, metabolism)
  • Cytoskeleton (genetics, metabolism)
  • Excitatory Amino Acid Transporter 1 (genetics, metabolism)
  • Glutamate Decarboxylase (genetics, metabolism)
  • Infarction, Middle Cerebral Artery (genetics, metabolism)
  • Intercellular Signaling Peptides and Proteins (genetics, metabolism)
  • Male
  • Myelin Proteins (genetics, metabolism)
  • NF-kappa B (genetics, metabolism)
  • Nerve Tissue Proteins (genetics, metabolism)
  • Neurotransmitter Agents (genetics, metabolism)
  • Nogo Proteins
  • Proteome (genetics, metabolism)
  • Proteomics (methods)
  • Quantitative Trait Loci (genetics)
  • Rats
  • Rats, Sprague-Dawley
  • Recombinant Proteins (genetics, metabolism)
  • Reperfusion Injury (genetics, metabolism)
  • Stroke (genetics, metabolism)
  • Tissue Plasminogen Activator (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: